Antisense oligonucleotides

Antisense oligonucleotides has been studied in 44 papers since 2017: none in people yet, 4 in animals, 2 in cells, 38 reviews; 36 in the past year. The research so far is in animals and cells. The newest paper, Nov 17, 2026: “Machine Learning-Guided Design of Peptide-Targeted CRISPR Vectors for Tissue-Specific Non-Coding RNA Knockdown”.

InterventionPreclinical

44 papers study it19 findingsUpdated

Research on it is growing 486% faster than aging research as a whole: 20 papers in the latest year counted

9 new papers in 30 daysSee all 43 papers on antisense oligonucleotides

At a glance

Antisense oligonucleotides extend lifespan in Hutchinson–Gilford progeria mouse models, a result independently reproduced in mice. In progeroid patient fibroblasts, L1 RNA depletion reduces epigenetic age and senescence-associated secretory phenotype gene expression. Most reported results involve authors at Altos Labs or Ionis Pharmaceuticals, and a paper declares ties to Ionis.

19 findings in 13 papers from 2017 to 2026, 4 of them since August 2026

The findings reach people, from one lab or study; independent labs found the same change in mice. 4 independent labs in 4 countries.

None of its findings points the other way.

Mice: replicated by independent labs. Cells and humans: a single group. Worms or flies: nothing yet.
  • 4 independent labs in 4 countries
  • Funders: National Cancer Institute and others
  • 7 of 10 findings with company ties
  • Animals4
  • Cells2

What did studies of antisense oligonucleotides find?

14

Studies of antisense oligonucleotides measured 14 outcomes; the most studied are lipoprotein (5 studies) and lifespan (2).

Lipoprotein

downin humans5−90%

5 studies
  1. Antisense oligonucleotides decrease lipoprotein in humans (Elevated Lp(a); ASO trials versus placebo) (−74 to −80 nmol/L).

    “ASO trials demonstrated more modest reductions (−74 to −80 nmol/L) with greater variability.”

    ReviewElevated Lp(a); ASO trials versus placebo

    RNA targeted therapies for lipoprotein(a) lowering: systematic review and meta analysis of siRNA and antisense oligonucleotides

    ESC Congress 2026 abstract

  2. Antisense oligonucleotides decrease lipoprotein in humans (65% to >95%).

    “RNA-targeted agents, comprising antisense oligonucleotides and small interfering RNAs, together with a first oral small-molecule inhibitor, lower Lp(a) by about 65% to more than 95%”

    Review

    Lipoprotein(a) in the statin era: from risk marker to therapeutic target

    Frontiers in pharmacology

  3. Antisense oligonucleotides decrease lipoprotein in humans (up to 90%).

    “Novel therapies-including antisense oligonucleotides, siRNA therapeutics, CETP inhibitors, and experimental gene-editing approaches-show promising potential, reducing Lp(a) levels by up to 90%.”

    Review

    Lipoprotein(a) as a Cardiovascular Risk Factor: Clinical Significance and Therapeutic Perspectives

    Biomedicines

  4. Antisense oligonucleotides decrease lipoprotein in humans (Phase II trials).

    “antisense oligonucleotides and small interfering RNAs) and a small molecule inhibitor of Lp(a) synthesis, demonstrated substantial and often durable Lp(a)-lowering effects in Phase II trials.”

    ReviewPhase II trials

    Lipoprotein(a)-lowering therapies: a promising future

    European heart journal

  5. Antisense oligonucleotides decrease lipoprotein in humans.

    “Novel therapeutics, including antisense oligonucleotides, small interfering RNAs, and small molecular inhibitors, have shown promising Lp(a)-lowering effects”

    Review

    A Position Paper on Lipoprotein(a) From the Lipoprotein(a) Task Force of the Korean Society of Lipid and Atherosclerosis: Current Evidence, Clinical Applications, and Future Directions

    Journal of lipid and atherosclerosis

More on Lipoprotein

Lifespan

upin mice2

2 studies
  1. Antisense oligonucleotides extend lifespan in mice (systemic delivery in a Hutchinson-Gilford progeria syndrome mouse model).

    “systemic delivery of ASOs rescued the histophysiology of tissues and increased the life span of a Hutchinson-Gilford progeria syndrome mouse model”

    Animalssystemic delivery in a Hutchinson-Gilford progeria syndrome mouse model

    LINE-1 RNA causes heterochromatin erosion and is a target for amelioration of senescent phenotypes in progeroid syndromes

    Science translational medicine

  2. Antisense oligonucleotides extend lifespan in mice (mouse model of HGPS).

    “Treatment with an optimized lead candidate resulted in extension of lifespan in a mouse model of HGPS.”

    Animalsmouse model of HGPSoptimized lead candidate targeting the LMNA exon 12 junction

    Systematic screening identifies therapeutic antisense oligonucleotides for Hutchinson-Gilford progeria syndrome

    Nature medicine

Angiotensinogen

downin humans1

1 study
  1. Antisense oligonucleotides inhibit angiotensinogen in humans (hypertension).

    “Antisense strategies have provided additional clinical validation of sustained angiotensinogen inhibition, although their antihypertensive efficacy has been less consistent.”

    Reviewhypertension

    Are Injectable Antihypertensives the Answer to Improving Blood Pressure Control: SiRNAs and Antisense Oligonucleotide Agents

    Current cardiology reports

More on Angiotensinogen

RNA splicing

upin reviews1

1 study
  1. Antisense oligonucleotides improve RNA splicing.

    “Therapeutic strategies to correct splicing defects, such as antisense oligonucleotides, RNA interference, CRISPR-Cas systems, ADAR-mediated editing, and RNA aptamers, can restore a homeostatic balance of mRNA isoforms.”

    Review

    Loss of Splicing Homeostasis as a Hallmark of Aging

    Molecular and cellular biology

More on RNA splicing

Atherogenic lipoproteins and triglycerides

downin reviews1

1 study
  1. Antisense oligonucleotides decrease atherogenic lipoproteins and triglycerides.

    “Small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs) targeting PCSK9, Lp(a), apo C-III and ANGPTL3 have shown marked efficacy in lowering atherogenic lipoproteins and triglycerides”

    Review

    Nucleic Acid-Based Therapies - The Next Frontier in Treating Dyslipidemias

    The Canadian journal of cardiology

More on Atherogenic lipoproteins and triglycerides

Inflammation

downin reviews1

1 study
  1. Antisense oligonucleotides decrease inflammation.

    “ASOs can offer targeted intervention against key pathological mechanisms such as protein aggregation, chronic inflammation, metabolic dysfunction, and tissue fibrosis by modulating gene expression.”

    Review

    Antisense Oligonucleotide Therapeutics Targeting Age-Related Diseases

    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

More on Inflammation

Protein aggregation

downin reviews1

1 study
  1. Antisense oligonucleotides decrease protein aggregation.

    “ASOs can offer targeted intervention against key pathological mechanisms such as protein aggregation, chronic inflammation, metabolic dysfunction, and tissue fibrosis by modulating gene expression.”

    Review

    Antisense Oligonucleotide Therapeutics Targeting Age-Related Diseases

    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Epigenetic age

downin human cells1

1 study
  1. Antisense oligonucleotides decrease epigenetic age in human cells (L1 RNA depletion in progeroid patient fibroblasts).

    “reversed DNA methylation age”

    CellsL1 RNA depletion in progeroid patient fibroblasts

    LINE-1 RNA causes heterochromatin erosion and is a target for amelioration of senescent phenotypes in progeroid syndromes

    Science translational medicine

More on Epigenetic age

senescence-associated secretory phenotype gene expression

downin human cells1

1 study
  1. Antisense oligonucleotides decrease senescence-associated secretory phenotype gene expression in human cells (L1 RNA depletion in progeroid patient fibroblasts).

    “counteracted the expression of senescence-associated secretory phenotype genes such as p16, p21, activating transcription factor 3 (ATF3)”

    CellsL1 RNA depletion in progeroid patient fibroblasts

    LINE-1 RNA causes heterochromatin erosion and is a target for amelioration of senescent phenotypes in progeroid syndromes

    Science translational medicine

Histone H3 lysine 9 and lysine 27 trimethylation

upin human cells1

1 study
  1. Antisense oligonucleotides increase histone H3 lysine 9 and lysine 27 trimethylation in human cells (L1 RNA depletion in dermal fibroblasts from patients with progeroid syndromes).

    “restored heterochromatin histone 3 lysine 9 and histone 3 lysine 27 trimethylation marks”

    CellsL1 RNA depletion in dermal fibroblasts from patients with progeroid syndromes

    LINE-1 RNA causes heterochromatin erosion and is a target for amelioration of senescent phenotypes in progeroid syndromes

    Science translational medicine

More on Histone H3 lysine 9 and lysine 27 trimethylation

All 14

Funding

6 grants since 2019

National Institute on Aging$5.9M

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Direct results come from one lab in mice: a preprint reports reduced pulmonary fibrosis and improved alveolar regeneration. Reviews describe lipoprotein reductions in humans. Beneficentia Stiftung Foundation is named on both findings, while National Institute on Aging funding appears in grants.

  2. Summary written from the findings.

Latest

Dec 2025: 1Jan 2026: 7Feb 2026: 2Mar 2026: 4Apr 2026: 0May 2026: 2Jun 2026: 1Jul 2026: 3Aug 2026: 5Sep 2026: 1Oct 2026: 5Nov 2026: 435 papers in 12 months

See all 43 papers on antisense oligonucleotides